Latest Healthcare News

Page 67 of 179
Unith Ltd reported a 19% revenue increase to $5.37 million for FY25, driven by its new Digital Human platform launch and B2C expansion, yet net losses widened significantly to $4.95 million. The company’s strategic partnerships and capital raise underpin its growth ambitions amid ongoing cash burn.
Sophie Babbage
Sophie Babbage
29 Aug 2025
Elanor Investors Group reported a substantial $157.8 million net loss for FY24 amid asset devaluations and debt covenant breaches, prompting a strategic recapitalisation and leadership transition.
Eva Park
Eva Park
29 Aug 2025
Althea Group Holdings reports a significant reduction in losses for FY25, driven by asset sales and strategic refocus on North American THC beverages. The company completed a $4 million capital raise and navigated leadership changes amid subsidiary liquidations.
Ada Torres
Ada Torres
29 Aug 2025
Uscom Limited reported a 25% decline in revenue to $3.16 million and a 59% increase in net loss to $3.3 million for FY25, reflecting significant global headwinds. Despite setbacks, the company advanced new product approvals and secured funding to navigate ongoing challenges.
Ada Torres
Ada Torres
29 Aug 2025
EZZ Life Science Holdings Limited reported a slight increase in revenue for the year ended June 2025, while net profit experienced a modest decline. The company also boosted its net tangible assets per share and maintained steady dividend payments.
Ada Torres
Ada Torres
29 Aug 2025
Cardiex Limited reported a 10% revenue increase in FY25, driven by new product launches and significant cost reductions, positioning the company for growth in FY26 with strong backing from C2 Ventures.
Ada Torres
Ada Torres
29 Aug 2025
Cardiex Limited’s FY2025 results reveal a sharp 67% revenue decline driven by the prior year’s one-off clinical trial payment, while net losses nearly doubled despite ongoing cost reduction efforts and significant capital raises.
Ada Torres
Ada Torres
29 Aug 2025
EVE Health Group has reported a 19% decline in revenue and a 17% increase in net loss for the financial year ended June 2025, highlighting ongoing challenges in its health and wellness segments.
Ada Torres
Ada Torres
29 Aug 2025
Cambium Bio reported a $3.84 million loss for FY25 but secured critical FDA approvals and ethics clearances to initiate Phase 3 trials of Elate Ocular®, supported by a $2.12 million capital raise.
Ada Torres
Ada Torres
29 Aug 2025
Firebrick Pharma reported a substantial increase in Nasodine Nasal Spray revenues in FY25, alongside a widening net loss driven by reduced R&D incentives and increased marketing investments. The company is advancing its international rollout with new licensing deals and board appointments.
Ada Torres
Ada Torres
29 Aug 2025
Hydrix Limited narrowed its FY2025 loss to $2.92 million, driven by significant cost reductions and steady revenue from expanding international medtech clients. Despite ongoing challenges in sales cycles and funding, the company remains focused on innovation and strategic investments.
Ada Torres
Ada Torres
29 Aug 2025
Optiscan Imaging Limited reported a 17.6% revenue decline and a 4.1% increase in net loss for FY25, driven by lower orders and higher R&D spending. The company unveiled two new medical imaging devices as it ramps up commercial efforts.
Ada Torres
Ada Torres
29 Aug 2025